Report cover image

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 199 Pages
SKU # APRC20276954

Description

Summary

According to APO Research, The global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs include Chugai Pharmaceutical, Regeneron Pharmaceuticals, Novartis, Roche, Amgen, Omeros Corporation, NovelMed, AstraZeneca and Apellis Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs sales, projected growth trends, production technology, application and end-user industry.

Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Segment by Company

Chugai Pharmaceutical
Regeneron Pharmaceuticals
Novartis
Roche
Amgen
Omeros Corporation
NovelMed
AstraZeneca
Apellis Pharmaceuticals
Alexion
Akari Therapeutics
Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Segment by Type

Oral Drugs
Injectable Drugs
Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Segment by Application

Pharmaceutical and Biotechnology Companies
Clinical
Others
Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

199 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size, 2020 VS 2024 VS 2031
1.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size Estimates and Forecasts (2020-2031)
1.4 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Estimates and Forecasts (2020-2031)
1.5 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Dynamics
2.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Trends
2.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Drivers
2.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Opportunities and Challenges
2.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Restraints
3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market by Manufacturers
3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Manufacturers (2020-2025)
3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Manufacturers (2020-2025)
3.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Sales Price by Manufacturers (2020-2025)
3.4 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturers, Product Type & Application
3.7 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market CR5 and HHI
3.8.2 Global Top 5 and 10 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Players Market Share by Revenue in 2024
3.8.3 2024 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Tier 1, Tier 2, and Tier 3
4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market by Type
4.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Type Introduction
4.1.1 Oral Drugs
4.1.2 Injectable Drugs
4.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type
4.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2020-2031)
4.2.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Type (2020-2031)
4.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Type
4.3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Type (2020-2031)
4.3.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Type (2020-2031)
5 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market by Application
5.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Application Introduction
5.1.1 Pharmaceutical and Biotechnology Companies
5.1.2 Clinical
5.1.3 Others
5.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application
5.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2020-2031)
5.2.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Application (2020-2031)
5.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Application
5.3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Application (2020-2031)
5.3.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Application (2020-2031)
6 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region
6.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region (2020-2031)
6.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region (2020-2025)
6.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Region
7.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Region
7.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Region (2020-2025)
7.1.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Region (2026-2031)
7.1.4 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue (2020-2031)
7.2.2 North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue (2020-2031)
7.3.2 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue (2020-2031)
7.4.2 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Chugai Pharmaceutical
8.1.1 Chugai Pharmaceutical Comapny Information
8.1.2 Chugai Pharmaceutical Business Overview
8.1.3 Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
8.1.5 Chugai Pharmaceutical Recent Developments
8.2 Regeneron Pharmaceuticals
8.2.1 Regeneron Pharmaceuticals Comapny Information
8.2.2 Regeneron Pharmaceuticals Business Overview
8.2.3 Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
8.2.5 Regeneron Pharmaceuticals Recent Developments
8.3 Novartis
8.3.1 Novartis Comapny Information
8.3.2 Novartis Business Overview
8.3.3 Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
8.3.5 Novartis Recent Developments
8.4 Roche
8.4.1 Roche Comapny Information
8.4.2 Roche Business Overview
8.4.3 Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
8.4.5 Roche Recent Developments
8.5 Amgen
8.5.1 Amgen Comapny Information
8.5.2 Amgen Business Overview
8.5.3 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
8.5.5 Amgen Recent Developments
8.6 Omeros Corporation
8.6.1 Omeros Corporation Comapny Information
8.6.2 Omeros Corporation Business Overview
8.6.3 Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
8.6.5 Omeros Corporation Recent Developments
8.7 NovelMed
8.7.1 NovelMed Comapny Information
8.7.2 NovelMed Business Overview
8.7.3 NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
8.7.5 NovelMed Recent Developments
8.8 AstraZeneca
8.8.1 AstraZeneca Comapny Information
8.8.2 AstraZeneca Business Overview
8.8.3 AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
8.8.5 AstraZeneca Recent Developments
8.9 Apellis Pharmaceuticals
8.9.1 Apellis Pharmaceuticals Comapny Information
8.9.2 Apellis Pharmaceuticals Business Overview
8.9.3 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
8.9.5 Apellis Pharmaceuticals Recent Developments
8.10 Alexion
8.10.1 Alexion Comapny Information
8.10.2 Alexion Business Overview
8.10.3 Alexion Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Alexion Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
8.10.5 Alexion Recent Developments
8.11 Akari Therapeutics
8.11.1 Akari Therapeutics Comapny Information
8.11.2 Akari Therapeutics Business Overview
8.11.3 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio
8.11.5 Akari Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Value Chain Analysis
9.1.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Mode & Process
9.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Distributors
9.2.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.